14 nations, including Russia, Brazil and China, are in the process of applying to use in their hospitals Heberprot-P, a Cuban medicine which is the only one of its kind in the world capable of stimulating the growth of tissues and reversing acute lesions in the feet of diabetic patients.
Lawyer Erick Hernandez Leyva, a specialist of the Management Group for Promotion of the Center for Genetic Engineering and Biotechnology, said the drug has helped more than 200,000 people in Cuba and the world afflicted with diabetic foot ulcers in advanced and high risk of amputation.
“At present 18 countries, including the Bolivarian Republic of Venezuela, Ecuador, Algeria, Mexico and Angola, have been granted the sanitary registration for use of this drug,” said the specialist, who is participating in actions to extend coverage of the drug in the ten municipalities of Ciego de Avila.
In Cuba at present there are 348 medical centres and more than a thousand professionals trained in providing therapy as part of the National Programme for Diabetic Patients with foot lesions, by using advanced technologies through Heberprot-P.
For his part, Dr. Mislene Álvarez Hernández, head of the program and Angiology Services, noted that the ten municipalities of the province have at least one hospital that has qualified personnel to apply this medicine for free to the public.
Heberprot-P is a drug produced by CIGTB, and is the only treatment of its kind in the world. It is used in the replacement of foot tissue severely damaged by diabetes, and its application has caused a considerable decrease in the risk of amputation and hospital stay, according to impact studies.